At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NOVN Novan Inc.
Delisted 12-23 05:48:39 EST
0.0941
+0.0000
0.00%
High0.0941
Low0.0941
Vol0.00
Open0.0941
D1 Closing0.0941
Amplitude0.00%
Mkt Cap2.64M
Tradable Cap2.40M
Total Shares28.02M
T/O0.00
T/O Rate0.00%
Tradable Shares25.52M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novartis AG (Six Swiss: CH:NOVN), CompuGroup Medical (GB:0MSD) and GlaxoSmithKline (GB:GSK)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevation Oncology (ELEV), Novartis AG (Six Swiss: CH:NOVN) and VBI Vaccines (VBIV)
Us FDA Approves Expanded Indication For Novartis Leqvio (Inclisiran) To Include Treatment Of Adults With High Ldl-C And Who Are At Increased Risk Of Heart Disease
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.